https://médecine.top/index.php?action=history&feed=atom&title=Syndrome_coronarien_aigu_%28SCA%29
Syndrome coronarien aigu (SCA) - Historique des versions
2026-09-04T17:07:32Z
Historique des révisions pour cette page sur le wiki
MediaWiki 1.35.2
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4852&oldid=prev
Julien : /* Traitement au long cours selon sous-groupes */
2023-09-27T15:31:22Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours selon sous-groupes</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 27 septembre 2023 à 15:31</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l126" >Ligne 126 :</td>
<td colspan="2" class="diff-lineno">Ligne 126 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">** <u>Syndrome coronarien aigu et FEVG diminuée:</u></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*** Beta-blockers are recommended in ACS patients with LVEF ≤40% regardless of HF symptoms (classe IA ESC 2023).</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-2022-322115 Ishak D, Aktaa S, Lindhagen L, et al Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes Heart Published Online First: 02 May 2023]</ref>. Stratégie possible: ETT de contrôle à 12 mois et poursuite du β-bloquant si FEVG diminuée.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-2022-322115 Ishak D, Aktaa S, Lindhagen L, et al Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes Heart Published Online First: 02 May 2023]</ref>. Stratégie possible: ETT de contrôle à 12 mois et poursuite du β-bloquant si FEVG diminuée.</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4823&oldid=prev
Julien : /* Traitement au long cours selon sous-groupes */
2023-07-08T08:51:40Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours selon sous-groupes</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 8 juillet 2023 à 08:51</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l126" >Ligne 126 :</td>
<td colspan="2" class="diff-lineno">Ligne 126 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-2022-322115 Ishak D, Aktaa S, Lindhagen L, et al<del class="diffchange diffchange-inline">. </del>Heart <del class="diffchange diffchange-inline">Epub ahead of print</del>: <del class="diffchange diffchange-inline">08.07.</del>2023]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-2022-322115 Ishak D, Aktaa S, Lindhagen L, et al <ins class="diffchange diffchange-inline">Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes </ins>Heart <ins class="diffchange diffchange-inline">Published Online First</ins>: <ins class="diffchange diffchange-inline">02 May </ins>2023]</ref>. Stratégie possible: ETT de contrôle à 12 mois et <ins class="diffchange diffchange-inline">poursuite du β-bloquant </ins>si <ins class="diffchange diffchange-inline">FEVG diminuée.</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4822&oldid=prev
Julien : /* Traitement au long cours selon sous-groupes */
2023-07-08T08:47:36Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours selon sous-groupes</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 8 juillet 2023 à 08:47</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l126" >Ligne 126 :</td>
<td colspan="2" class="diff-lineno">Ligne 126 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-<del class="diffchange diffchange-inline">2023</del>-<del class="diffchange diffchange-inline">322544 </del>Ishak D, Aktaa S, Lindhagen L, et al. Heart Epub ahead of print: 08.07.2023]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-<ins class="diffchange diffchange-inline">2022</ins>-<ins class="diffchange diffchange-inline">322115 </ins>Ishak D, Aktaa S, Lindhagen L, et al. Heart Epub ahead of print: 08.07.2023]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4821&oldid=prev
Julien : /* Traitement au long cours selon sous-groupes */
2023-07-08T08:44:39Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours selon sous-groupes</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 8 juillet 2023 à 08:44</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l126" >Ligne 126 :</td>
<td colspan="2" class="diff-lineno">Ligne 126 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-2023-322544 Ishak D, Aktaa S, Lindhagen L, et al. Heart Epub ahead of print: 08.07.2023<del class="diffchange diffchange-inline">. doi:10.1136/ heartjnl-2022-322115</del>]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[https://dx.doi.org/10.1136/heartjnl-2023-322544 Ishak D, Aktaa S, Lindhagen L, et al. Heart Epub ahead of print: 08.07.2023]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4820&oldid=prev
Julien : /* Traitement au long cours selon sous-groupes */
2023-07-08T08:42:48Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours selon sous-groupes</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 8 juillet 2023 à 08:42</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l126" >Ligne 126 :</td>
<td colspan="2" class="diff-lineno">Ligne 126 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[<del class="diffchange diffchange-inline">http</del>://dx.doi.org/10.1136/ heartjnl-2023-322544 Ishak D, Aktaa S, Lindhagen L, et al. Heart Epub ahead of print: 08.07.2023. doi:10.1136/ heartjnl-2022-322115]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[<ins class="diffchange diffchange-inline">https</ins>://dx.doi.org/10.1136/heartjnl-2023-322544 Ishak D, Aktaa S, Lindhagen L, et al. Heart Epub ahead of print: 08.07.2023. doi:10.1136/ heartjnl-2022-322115]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4819&oldid=prev
Julien : /* Traitement au long cours selon sous-groupes */
2023-07-08T08:39:07Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours selon sous-groupes</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 8 juillet 2023 à 08:39</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l126" >Ligne 126 :</td>
<td colspan="2" class="diff-lineno">Ligne 126 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours selon sous-groupes ==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''β-bloquant:'''</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>** <u>STEMI et FEVG préservée:</u> <ins class="diffchange diffchange-inline">pas de bénéfice prouvé de la poursuite du bêta-bloquant au-delà de 12 mois<ref>[http://dx.doi.org/10.1136/ heartjnl-2023-322544 Ishak D, Aktaa S, Lindhagen L, et al. Heart Epub ahead of print: 08.07.2023. doi:10.1136/ heartjnl-2022-322115]</ref>. Stratégie possible: ETT de contrôle à 12 mois et si </ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4649&oldid=prev
Julien : /* Traitement au long cours selon sous-groupes */
2022-05-29T12:00:34Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours selon sous-groupes</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 29 mai 2022 à 12:00</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l129" >Ligne 129 :</td>
<td colspan="2" class="diff-lineno">Ligne 129 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>** <u>NSTEMI et FEVG préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ref></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* '''Diurétique d'épargne potassique'''</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <u>FEVG réduite ≤40% après STEMI:</u></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">*</ins>* <u>FEVG réduite ≤40% après STEMI:</u> diurétique d'épargne potassique = spironolactone</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">** </del>diurétique d'épargne potassique = spironolactone</div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4648&oldid=prev
Julien : /* Traitement au long cours */
2022-05-29T12:00:06Z
<p><span dir="auto"><span class="autocomment">Traitement au long cours</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 29 mai 2022 à 12:00</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l124" >Ligne 124 :</td>
<td colspan="2" class="diff-lineno">Ligne 124 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|}</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|}</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">=</del>== Traitement au long cours ==<del class="diffchange diffchange-inline">=</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>== Traitement au long cours <ins class="diffchange diffchange-inline">selon sous-groupes </ins>==</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <del class="diffchange diffchange-inline">Si </del>FEVG <<del class="diffchange diffchange-inline">= 40</del>%: <del class="diffchange diffchange-inline">ad </del>diurétique d'épargne potassique = spironolactone</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins class="diffchange diffchange-inline">'''β-bloquant:'''</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">** <u>STEMI et FEVG préservée:</u></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">** <u>NSTEMI et </ins>FEVG <ins class="diffchange diffchange-inline">préservée:</u> in patients with non-ST segment elevation acute coronary syndromes and preserved EF, the 2014 ACC/AHA guidelines give a Class IIa (level of evidence C) recommendation for long-term beta-blocker use, while the 2015 ESC guidelines offer no such recommendations.<ref>https://academic.oup.com/eurheartj/article/41/37/3530/5879119</ins><<ins class="diffchange diffchange-inline">/ref></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">* '''Diurétique d'épargne potassique'''</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">* <u>FEVG réduite ≤40</ins>% <ins class="diffchange diffchange-inline">après STEMI</ins>:<ins class="diffchange diffchange-inline"></u></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">** </ins>diurétique d'épargne potassique = spironolactone</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4647&oldid=prev
Julien : /* Définition */
2022-05-29T11:01:27Z
<p><span dir="auto"><span class="autocomment">Définition</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 29 mai 2022 à 11:01</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l34" >Ligne 34 :</td>
<td colspan="2" class="diff-lineno">Ligne 34 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Associé à une intervention coronarienne percutanée</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Associé à une intervention coronarienne percutanée</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| </div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| Elévation <del class="diffchange diffchange-inline">≥ 5 fois </del>de la hs-cTn de base ou > 20 % en cas de valeur de base pathologique dans un contexte de cathétérisme cardiaque</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| Elévation <ins class="diffchange diffchange-inline">≥5× </ins>de la hs-cTn de base ou >20 % en cas de valeur de base pathologique dans un contexte de cathétérisme cardiaque</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| IVb</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| IVb</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l49" >Ligne 49 :</td>
<td colspan="2" class="diff-lineno">Ligne 49 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Associé à bypass aorto-coronarien</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| Associé à bypass aorto-coronarien</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| </div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>| Elévation <del class="diffchange diffchange-inline">≥ 5 fois </del>de la hs-cTn de base ou > 20 % en cas de valeur de base pathologique dans un contexte de chirurgie cardiaque</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>| Elévation <ins class="diffchange diffchange-inline">≥5× </ins>de la hs-cTn de base ou >20 % en cas de valeur de base pathologique dans un contexte de chirurgie cardiaque</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|}</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|}</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
</table>
Julien
https://médecine.top/index.php?title=Syndrome_coronarien_aigu_(SCA)&diff=4646&oldid=prev
Julien : /* STEMI */
2022-05-29T10:59:38Z
<p><span dir="auto"><span class="autocomment">STEMI</span></span></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="fr">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 29 mai 2022 à 10:59</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l79" >Ligne 79 :</td>
<td colspan="2" class="diff-lineno">Ligne 79 :</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== STEMI ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== STEMI ==</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">=== Evaluation et prise en charge initiale ===</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>=== Critères ===</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">* Evaluation médicale</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">* Anamnèse ciblée: Début des symptômes ? Allergie à l'aspirine ? Dernier repas ? Usage de stimulants sexuels (ou vasodilatateurs pulmonaires) ?</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">* Monitoring = scope</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">* Pose de 2 VVP</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">* ECG</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>=== Critères <del class="diffchange diffchange-inline">de STEMI </del>===</div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Diagnostic: critère clinique ET 1 critère ECG</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Diagnostic: critère clinique ET 1 critère ECG</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
</table>
Julien